Advances of Connexin 43-mediated glioma temozolomide resistance

QIN Hongkun; GUI Yanping; WANG Yajing; ZHAO Li

doi:10.11665/j.issn.1000-5048.20180602

Journal of China Pharmaceutical University > 2018 > 49(6): 646-652. > DOI: 10.11665/j.issn.1000-5048.20180602

QIN Hongkun, GUI Yanping, WANG Yajing, ZHAO Li. Advances of Connexin 43-mediated glioma temozolomide resistance[J]. Journal of China Pharmaceutical University, 2018, 49(6): 646-652. DOI: 10.11665/j.issn.1000-5048.20180602

Citation:

PDF (1731 KB)

Advances of Connexin 43-mediated glioma temozolomide resistance

More Information

Graphical Abstract

Abstract

Abstract

Gap junction is a necessary channel structure composed of connexin proteins, which can form direct communication to exchange material and information between mammal cells. Connexin 43(Cx43)is the most abundant connexin protein expressed in the central nervous system. There is emerging evidence that Cx43 has a wide regulatory effect on the occurrence and development of glioma and play an important role in malignant biological behaviors of glioma. Temozolomide is a currently first-line chemotherapeutic drug for glioma. However, with the prolong of treatment period, the therapy effect of temozolomide is attenuated in some patients because of drug resistance. And the abnormal expression of Cx43 in glioma may be one of the important reasons for temozolomide resistance. In this review, we summarized the structure and function of Cx43, several mechanism of temozolomide resistance and the research progress of Cx43-mediated temozolomide resistance, as well as anti-tumor compounds targeting Cx43 in recent years, in order to provide new evidence for glioma therapy.
- glioma,
- gap junction,
- temozolomide,
- drug resistance,
- advances

FullText(HTML)

References (70)

References

[1]	Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2]	Gallego O.Nonsurgical treatment of recurrent glioblastoma[J].Curr Oncol,2015,22(4):e273-281.
[3]	Wang X,Chen JX,Liu JP,et al.Gain of function of mutant TP53 in glioblastoma:prognosis and response to temozolomide[J].Ann Surg Oncol,2014,21(4):1337-1344.
[4]	Stupp R,Mason WP,Van DB,Martin J,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J].N Engl J Med,2008,2(10):421-422.
[5]	Cavaliere R,Wen PY,Schiff D.Novel therapies for malignant gliomas[J].Neurol Clin,2007,25(4):1141-1171.
[6]	Chen Q,Boire A,Jin X,et al.Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer[J].Nature,2016,533(7604):493-498.
[7]	Aasen T,Mesnil M,Naus CC,et al.Gap junctions and cancer:communicating for 50 years[J].Nat Rev Cancer,2016,16(12):775-788.
[8]	Maeda S,Nakagawa S,Suga M,et al.Structure of the human connexin 26 Gap junction channel[J].Nature,2009,458(7238):597-602.
[9]	Solan JL,Lampe PD.Specific Cx43 phosphorylation events regulate gap junction turnover in vivo[J].FEBS Lett,2014,588(8):1423-1429.
[10]	Desplantez T, Verma V, Leybaert L, et al. Gap26,a connexin mimetic peptide,inhibits currents carried by Connexin 43 hemichannels and gap junction channels[J].Pharmacol Res,2012,65(5):546-552.
[11]	Iyyathurai J,Wang N,D′hondt C,et al.The SH3-binding domain of Cx43 participates in loop/tail interactions critical for Cx43-hemichannel activity[J].Cell Mol Life Sci,2017,75(1):1-15.
[12]	Khan Z,Yaiw K-C,Wilhelmi V,et al.Human cytomegalovirus immediate early proteins promote degradation of Connexin 43 and disrupt gap junction communication:implications for a role in gliomagenesis[J].Carcinogenesis,2013,35(1):145-154.
[13]	Sin W,Aftab Q,Bechberger J,et al.Astrocytes promote glioma invasion via the gap junction protein Connexin 43[J].Oncogene,2016,35(12):1504-1516.
[14]	Aasen T.Connexins:junctional and non-junctional modulators of proliferation[J].Cell Tissue Res,2015,360(3):685-699.
[15]	Gielen PR,Aftab Q,Ma N,et al.Connexin 43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway[J].Neuropharmacology,2013,75(12):539-548.
[16]	Crespin S,Fromont G,Wager M,et al.Expression of a gap junction protein,Connexin 43,in a large panel of human gliomas:new insights[J].Cancer Med,2016,5(8):1742-1752.
[17]	Caltabiano R,Torrisi A,Condorelli D,et al.High levels of Connexin 43 mRNA in high grade astrocytomas.Study of 32 cases with in situ hybridization[J].Acta Histochem,2010,112(6):529-535.
[18]	Hegi ME,Diserens A-C,Gorlia T,et al.MGMT gene silencing and benefit from temozolomide in glioblastoma[J].N Engl J Med,2005,352(10):997-1003.
[19]	S Srivenugopal K,Rawat A,K Niture S,et al.Posttranslational regulation of O⁶-methylguanine-DNA methyltransferase(MGMT)and new opportunities for treatment of brain cancers[J].Mini Rev Med Chem,2016,16(6):455-464.
[20]	Molenaar RJ,Verbaan D,Lamba S,et al.The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone[J].Neuro Oncol,2014,16(9):1263-1273.
[21]	Brandes AA,Franceschi E,Tosoni A,et al.MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients[J].J Clin Oncol,2008,26(13):2192-2197.
[22]	Hirohata T,Asano K,Ogawa Y,et al.DNA mismatch repair protein(MSH6)correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide:the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors[J].J Clin Endocr Metab,2013,98(3):1130-1136.
[23]	Van Thuijl HF, Mazor T, Johnson BE, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment[J].Acta Neuropathol,2015,129(4):597-607.
[24]	Boccard SG,Marand SV,Geraci S,et al.Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment:a pre-clinical study[J].Oncotarget,2015,6(30):29456-29468.
[25]	Pasqualetti F,Gonnelli A,Cantarella M,et al.Association of glutathione S-transferase P-1(GSTP-1)rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy[J].Invest New Drugs,2018,36(2):340-345.
[26]	Wu C-P,Ambudkar SV.The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy[J].Acta Pharm Sin B,2014,4(2):105-111.
[27]	Schaich M,Kestel L,Pfirrmann M,et al.A MDR1(ABCB1)gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients[J].Ann Oncol,2008,20(1):175-181.
[28]	Munoz JL,Walker ND,Scotto KW,et al.Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells[J].Cancer Lett,2015,367(1):69-75.
[29]	He J, Liu C, Wang B, et al. HMGN5 blockade by siRNA enhances apoptosis,suppresses invasion and increases chemosensitivity to temozolomide in meningiomas[J].Int J Oncol,2015,47(4):1503-1511.
[30]	Moiseeva N,Susova OY,Mitrofanov A,et al.Connection between proliferation rate and temozolomide sensitivity of primary glioblastoma cell culture and expression of YB-1 and LRP/MVP[J].Biochemistry(Mosc),2016,81(6):628-635.
[31]	Lin F,De Gooijer MC,Roig EM,et al.ABCB1,ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy[J].Clin Cancer Res,2014,20(10):2703-2713.
[32]	Klionsky DJ,Abdelmohsen K,Abe A,et al.Guidelines for the use and interpretation of assays for monitoring autophagy[J].Autophagy,2016,12(1):1-222.
[33]	Ciechomska I,Gabrusiewicz K,Szczepankiewicz A,et al.Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine a-induced cell death[J].Oncogene,2013,32(12):1518-1529.
[34]	Knizhnik AV,Roos WP,Nikolova T,et al.Survival and death strategies in glioma cells:autophagy,senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage[J].PLoS One,2013,8(1):e55665.
[35]	Galluzzi L, Bravo-San Pedro JM, Demaria S, et al. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy[J].Nat Rev Clin Oncol,2017,14(4):247-258.
[36]	Golden EB, Cho HY, Jahanian A, et al. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy[J].Neurosurg Focus,2014,37(6):E12.
[37]	Lee SW,Kim HK,Lee NH,et al.The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells[J].Cancer Lett,2015,360(2):195-204.
[38]	Hori YS,Hosoda R,Akiyama Y,et al.Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells[J].J Neurooncol,2015,122(1):11-20.
[39]	U.S.National library of medicine.International Cooperative Phase III trial of the HIT-HGG study group(HIT-HGG-2013)[EB/OL].(2018-08-08)[2018-09-20] .https://Clinical Trials.gov/show/NCT03243461.
[40]	U.S.National Library of Medicine.The Addition of Chloroquine to Chemoradiation for Glioblastoma[EB/OL].(2018-03-21)[2018-09-20] .https://ClinicalTrials.gov/show/NCT02432417.
[41]	Lu J,Yu M,Lin Z,et al.Effects of Connexin 43 overexpression on U251 cell growth,migration,and apoptosis[J].Med Sci Mon Int Med J Exp Clin Res,2017,23:2917-2923.
[42]	Munoz JL, Rodriguez-Cruz V, Greco SJ, et al. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of Connexin 43[J].Cell Death Dis,2014,5(3):e1145.
[43]	Beahm DL,Oshima A,Gaietta G汍猬?睩椾瑥桴漠畡瑬?愯汩琾攮牍極湴条?杩慯灮?橯畦渠捡琠楣潯湮慳汥?捶潥浤洠畴湨楲捥慯瑮楩潮湥?楩湮?慴獨瑥爠潴捨祩瑲敤猠孴?嵡??業??牢潲湡瑮??敨汥汬?乸攠畯牦漠玱挠楡??椠???は????扩????扲???づ???戠牤??孩??嵮??奮略?????潥渠杣?卯女?奤甠????楪??散瑴?慯汮???楡?呮潥瑬慛汊?昮氼慩瘾潊渠潂楩摯獬?潃晨?汭椼琯獩放愬′挰漰爵攬愼湢愾′攸渱格愯湢挾攨?琲栩攺?挹礹琴漭琸漰砰椹挮椼瑢祲?漾晛?漴硝愠氠楃灡汯愠瑙椬湌?戠祔?楐湡据爠敘愼獩椾測来?朠慡灬?樼甯湩挾瑃楯潲湲?楬湡瑴敩牯据攠汯汦甠汥慸牰?捥潳浳浩畯湮椠捯慦琠楣潯湮孮?嵸??椠??椠潧汲?偷桴慨爠浡??甠汰汲??楲???ど????扦?????扩?????????????㈠??戾物??孳??嵵???椾??慝献椼????敩扮漠晊映敃????敲??慩爾椬渲椰猰‵??楢??攴琼?慢氾???椺?制攷琭椵渷漲椮挼?慲振椾摛?爵敝挠攠灙瑵潬特獡?晡爠潙洬?浮潤污敹捡甠求慂爬?浧攠捗案愼湩椾猬浥獴?瑡潬?挼愯湩挾敃牡?瑢桥敮牯慸灯祬孯?嵥??楮??潮汣??猠灔敒捁瑉獌??敮摤??楥???ば????扳??ㄠ??扲????ㄠ????扵牰??孧??嵡??坯慮渠杯?夠?坥慡湴杨?兲?婣桥慰湴杯?匠?椠??敤琠?慮汨???楴??慮椠捯慦氠敇楡湰?楪湵据牣整慩獯敮猠?瑮桴敥?捣祥瑬潬瑵潬硡楲挠楣瑯祭?潵普?捣楡獴灩汯慮琠楩湮?扨祵?敡湮栠慧湬捩楯湭条?杊慝瀮?橩甾湓捴瑥業漠湃?楬湬瑳攠牄捥敶氼氯畩氾愬爲‰挱漳洬洼畢渾椲挲愼琯楢漾渨嬱?崩??椸??漭氱??攲搮?剢敲瀯漾牛琴??椠???ぬ????戠??ぅ??扡??ㄠ???????????戬牥??孡??崼???潃湡歲汢楥湮?????敮捥栠扥敮牨条敮牣?????慁捉晌愭扩敮???楥??敡瑰?慰汴???楳??敨湲楯獵瑧敨椠湴?慥渠摵?煲略敧牵捬敡瑴楩湯?椠湯捦爠敤慥獡整?挠潲湥湣敥硰楴湯????慡湮摤?獩畮灨灩牢敩獴獩?杮爠潯睦琠桧?潰映?扵牮散慴獩瑯?挠慩湮捴敥牲?捥敬汬汵獬孡?崠??業??慮物捣楡湴潩杯敮渠敩獮椠獨??楡???ぬど???扛?????戾?????????び???扶爼??嬾??崰?″?攼牢渾稲眲攼椯杢￣??″?攺椱游椷朰攭爱????值牢慲猯愾楛渴???椠???攠瑓?愬汈???楧???測瑌楩?戠牙敓愼獩琾?捥慴渠捡敬爮?愯杩放湄瑩獦?煥畲楥湮潴汩楡湬攠獣?瑡慲牡杣整瑥楲湩杺?杴慩灯?樠畯湦挠瑴楥潭湯孺?嵬??楩??攭摲??桩敳浴??楴???ね????扬????戠?????????????nt J Mol Sci,2018,19(1):127.
[44]	Murphy SF,Varghese RT,Lamouille S,et al.Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide[J].Cancer Res,2016,76(1):139-149.
[45]	Quail DF,Joyce JA.The microenvironmental landscape of brain tumors[J].Cancer Cell,2017,31(3):326-341.
[46]	Herculano‐Houzel S.The glia/neuron ratio:how it varies uniformly across brain structures and species and what that means for brain physiology and evolution[J].Glia,2014,62(9):1377-1391.
[47]	Iadecola C,Nedergaard M.Glial regulation of the cerebral microvasculature[J].Nat Neurosci,2007,10(11):1369-1376.
[48]	Bazargani N,Attwell D.Astrocyte calcium signaling:the third wave[J].Nat Neurosci,2016,19(2):182-189.
[49]	Pekny M,Nilsson M.Astrocyte activation and reactive gliosis[J].Glia,2005,50(4):427-434.
[50]	Liddelow SA,Barres BA.Reactive astrocytes:production,function,and therapeutic potential[J].Immunity,2017,46(6):957-967.
[51]	Sofroniew MV.Reactive astrocytes in neural repair and protection[J].Neuroscientist,2005,11(5):400-407.
[52]	Lin Q,Balasubramanian K,Fan D,et al.Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels[J].Neoplasia,2010,12(9):748-754.
[53]	Li J, Zhang N, Song LB, et al. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival[J].Clin Cancer Res,2008,14(11):3319-3326.
[54]	Yu T,Wang X,Zhi T,et al.Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype[J].Cancer Lett,2018,433:210-220.
[55]	Yang N,Yan T,Zhu H,et al.A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma[J].J Transl Med,2014,12(1):1-9.
[56]	Lin Q,Liu Z,Ling F,et al.Astrocytes protect glioma cells from chemotherapy and upregulate survival genes via gap junctional communication[J].Mol Med Report,2016,13(2):1329-1335.
[57]	Sforna L,Cenciarini M,Belia S,et al.The role of ion channels in the hypoxia-induced aggressiveness of glioblastoma[J].Front Cell Neurosci,2015,8:467.
[58]	Chen W,Wang D,Du X,et al.Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes[J].Med Oncol,2015,32(3):43.
[59]	Hong X,Sin WC,Harris AL,et al.Gap junctions modulate glioma invasion by direct transfer of microRNA[J].Oncotarget,2015,6(17):15566-15577.
[60]	Ismail FS, Moinfar Z, Prochnow N, et al. Dexamethasone and levetiracetam reduce hetero-cellular gap-junctional coupling between F98 glioma cells and glial cells in vitro[J].J Neurooncol,2017,131(3):469-476.
[61]	Matias D,Predes D,Niemeyer Filho P,et al.Microglia-glioblastoma interactions:new role for Wnt signaling[J].BBA-Rev Cancer,2017,1868(1):333-340.
[62]	Quail DF,Bowman RL,Akkari L,et al.The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas[J].Science,2016,352(6288):aad3018.
[63]	Garg AD,Vandenberk L,Koks C,et al.Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma[J].Sci Transl Med,2016,8(328):328ra327.
[64]	Leshchenko Y,Likhodii S,Yue W,et al.Carbenoxolone does not cross the blood brain barrier:an HPLC study[J].BMC Neurosci,2006,7(1):3.
[65]	Chekhonin VP,Baklaushev VP,Yusubalieva GM,et al.Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43[J].Nanomed-Nanotechnol,2012,8(1):63-70.
[66]	Yusubalieva G,Baklaushev V,Gurina O,et al.Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment,temozolomide,and radiotherapy[J].Bull Exp Biol Med,2014,157(4):510-515.
[67]	Wang J,Yang ZY,Guo YF,et al.Targeting different domains of gap junction protein to control malignant glioma[J].Neuro Oncol,2017,20(7):885-896.
[68]	Li M,Liang RF,Wang X,et al.BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway[J].Oncol Lett,2017,14(6):6597-6603.
[69]	Ponsaerts R,De Vuyst E,Retamal M,et al.Intramolecular loop/tail interactions are essential for connexin 43-hemichannel activity[J].FASEB J,2010,24(11):4378-4395.
[70]	Abudara V,Bechberger J,Freitas-Andrade M,et al.The connexin 43 mimetic peptide Gap19 inhibits hemichanne

[1]	XIA Ying, GUO Hongli, HU Yahui, CHEN Feng. Therapeutic drug monitoring for monoclonal antibody：progress in the application of LC-MS/MS technique[J]. Journal of China Pharmaceutical University, 2021, 52(1): 122-128. DOI: 10.11665/j.issn.1000-5048.20210117
[2]	JI Shunli, SONG Fanfan, ZHENG Yang, DING Li. Simultaneous determination of amoxicillin and clavulanic acid by LC-MS/MS in human plasma and its application to a bioequivalence study[J]. Journal of China Pharmaceutical University, 2019, 50(6): 699-706. DOI: 10.11665/j.issn.1000-5048.20190610
[3]	LIANG Feng, LI Duo, WANG Rongbin, SHU Chang, DING Li. Pharmacokinetics and absolute bioavailability of isoschaftoside in rat by LC-MS/MS[J]. Journal of China Pharmaceutical University, 2019, 50(1): 75-80. DOI: 10.11665/j.issn.1000-5048.20190110
[4]	LIU Chaoyi, ZHANG Ge, HANG Taijun, WANG Lei, ZHANG Xiaofei, SONG Min. Identification of related substances in rivaroxaban by LC-MS[J]. Journal of China Pharmaceutical University, 2015, 46(4): 450-457. DOI: 10.11665/j.issn.1000-5048.20150411
[5]	LI Jingjing, TAN Jingfu, YANG Jie, WANG Qiang. Pharmacokinetic study of corosolic acid in normal rats and diabetic rats by LC-MS[J]. Journal of China Pharmaceutical University, 2014, 45(1): 84-87. DOI: 10.11665/j.issn.1000-5048.20140115
[6]	YANG Youtian, MAO Baiyang, CHENG Lifei, SU Mengxiang, DI Bin. Identification of the related substances in telmisartan/amlodipine double layer tablets by LC-MS/MS[J]. Journal of China Pharmaceutical University, 2014, 45(1): 65-69. DOI: 10.11665/j.issn.1000-5048.20140111
[7]	MU Yanan, YANG Jin. Determination of epothilone B in human blood by LC-MS/MS and its application in phase I pharmacokinetics study[J]. Journal of China Pharmaceutical University, 2013, 44(1): 89-92. DOI: 10.11665/j.issn.1000-5048.20130115
[8]	SI Qian, CHEN Yuan-cheng, HUANG Li-hua, CHENG Yu, HE Hua, LIU Xiao-quan. Determination of nebivolol in human plasma by LC-MS/MS and study of its pharmacokinetics on the Chinese[J]. Journal of China Pharmaceutical University, 2011, 42(2): 136-140.
[9]	Determination of Ranolazine and Its Pharmacokinetics in Dog by LC-MS[J]. Journal of China Pharmaceutical University, 2004, (2): 59-62.
[10]	Determination of Clarithromycin in Human Plasma by LC-MS Method[J]. Journal of China Pharmaceutical University, 2004, (1): 52-55.

Cited By

Get Citation

PDF

XML

Article views (844) PDF downloads (1318)

Turn off MathJax

Article Contents

Abstract

References

Advances of Connexin 43-mediated glioma temozolomide resistance

Abstract

References

Related Articles

Catalog

Advances of Connexin 43-mediated glioma temozolomide resistance

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content